Table of Content

1 Report Overview
1.1 Dermatomyositis Drug Definition
1.2 Market by Type
1.2.1 Global Dermatomyositis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Abatacept
1.2.3 Baricitinib
1.2.4 Dalazatide
1.2.5 Immune Globulin
1.2.6 IMO-8400
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Dermatomyositis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Dermatomyositis Drug Sales
2.1 Global Dermatomyositis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Dermatomyositis Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Dermatomyositis Drug Revenue by Region
2.3.1 Global Dermatomyositis Drug Revenue by Region (2018-2023)
2.3.2 Global Dermatomyositis Drug Revenue by Region (2024-2034)
2.4 Global Dermatomyositis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Dermatomyositis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Dermatomyositis Drug Sales Quantity by Region
2.6.1 Global Dermatomyositis Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Dermatomyositis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Dermatomyositis Drug Sales Quantity by Manufacturers
3.1.1 Global Dermatomyositis Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Dermatomyositis Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Dermatomyositis Drug Sales in 2024
3.2 Global Dermatomyositis Drug Revenue by Manufacturers
3.2.1 Global Dermatomyositis Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Dermatomyositis Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Dermatomyositis Drug Revenue in 2024
3.3 Global Dermatomyositis Drug Sales Price by Manufacturers
3.4 Global Key Players of Dermatomyositis Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Dermatomyositis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Dermatomyositis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Dermatomyositis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Dermatomyositis Drug Sales Quantity by Type
4.1.1 Global Dermatomyositis Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Dermatomyositis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Dermatomyositis Drug Revenue by Type
4.2.1 Global Dermatomyositis Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Dermatomyositis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Dermatomyositis Drug Price by Type
4.3.1 Global Dermatomyositis Drug Price by Type (2018-2023)
4.3.2 Global Dermatomyositis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Dermatomyositis Drug Sales Quantity by Application
5.1.1 Global Dermatomyositis Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Dermatomyositis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Dermatomyositis Drug Revenue by Application
5.2.1 Global Dermatomyositis Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Dermatomyositis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Dermatomyositis Drug Price by Application
5.3.1 Global Dermatomyositis Drug Price by Application (2018-2023)
5.3.2 Global Dermatomyositis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Dermatomyositis Drug Sales by Company
6.1.1 North America Dermatomyositis Drug Revenue by Company (2018-2023)
6.1.2 North America Dermatomyositis Drug Sales Quantity by Company (2018-2023)
6.2 North America Dermatomyositis Drug Market Size by Type
6.2.1 North America Dermatomyositis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Dermatomyositis Drug Revenue by Type (2018-2034)
6.3 North America Dermatomyositis Drug Market Size by Application
6.3.1 North America Dermatomyositis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Dermatomyositis Drug Revenue by Application (2018-2034)
6.4 North America Dermatomyositis Drug Market Size by Country
6.4.1 North America Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Dermatomyositis Drug Revenue by Country (2018-2034)
6.4.3 North America Dermatomyositis Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Dermatomyositis Drug Sales by Company
7.1.1 Europe Dermatomyositis Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Dermatomyositis Drug Revenue by Company (2018-2023)
7.2 Europe Dermatomyositis Drug Market Size by Type
7.2.1 Europe Dermatomyositis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Dermatomyositis Drug Revenue by Type (2018-2034)
7.3 Europe Dermatomyositis Drug Market Size by Application
7.3.1 Europe Dermatomyositis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Dermatomyositis Drug Revenue by Application (2018-2034)
7.4 Europe Dermatomyositis Drug Market Size by Country
7.4.1 Europe Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Dermatomyositis Drug Revenue by Country (2018-2034)
7.4.3 Europe Dermatomyositis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Dermatomyositis Drug Sales by Company
8.1.1 China Dermatomyositis Drug Sales Quantity by Company (2018-2023)
8.1.2 China Dermatomyositis Drug Revenue by Company (2018-2023)
8.2 China Dermatomyositis Drug Market Size by Type
8.2.1 China Dermatomyositis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Dermatomyositis Drug Revenue by Type (2018-2034)
8.3 China Dermatomyositis Drug Market Size by Application
8.3.1 China Dermatomyositis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Dermatomyositis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Dermatomyositis Drug Sales by Company
9.1.1 APAC Dermatomyositis Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Dermatomyositis Drug Revenue by Company (2018-2023)
9.2 APAC Dermatomyositis Drug Market Size by Type
9.2.1 APAC Dermatomyositis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Dermatomyositis Drug Revenue by Type (2018-2034)
9.3 APAC Dermatomyositis Drug Market Size by Application
9.3.1 APAC Dermatomyositis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Dermatomyositis Drug Revenue by Application (2018-2034)
9.4 APAC Dermatomyositis Drug Market Size by Region
9.4.1 APAC Dermatomyositis Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Dermatomyositis Drug Revenue by Region (2018-2034)
9.4.3 APAC Dermatomyositis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Dermatomyositis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Dermatomyositis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Dermatomyositis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Dermatomyositis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 MedImmune LLC
11.1.1 MedImmune LLC Company Information
11.1.2 MedImmune LLC Overview
11.1.3 MedImmune LLC Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 MedImmune LLC Dermatomyositis Drug Products and Services
11.1.5 MedImmune LLC Dermatomyositis Drug SWOT Analysis
11.1.6 MedImmune LLC Recent Developments
11.2 Neovacs SA
11.2.1 Neovacs SA Company Information
11.2.2 Neovacs SA Overview
11.2.3 Neovacs SA Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Neovacs SA Dermatomyositis Drug Products and Services
11.2.5 Neovacs SA Dermatomyositis Drug SWOT Analysis
11.2.6 Neovacs SA Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Overview
11.3.3 Novartis AG Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Novartis AG Dermatomyositis Drug Products and Services
11.3.5 Novartis AG Dermatomyositis Drug SWOT Analysis
11.3.6 Novartis AG Recent Developments
11.4 Octapharma AG
11.4.1 Octapharma AG Company Information
11.4.2 Octapharma AG Overview
11.4.3 Octapharma AG Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Octapharma AG Dermatomyositis Drug Products and Services
11.4.5 Octapharma AG Dermatomyositis Drug SWOT Analysis
11.4.6 Octapharma AG Recent Developments
11.5 Pfizer Inc
11.5.1 Pfizer Inc Company Information
11.5.2 Pfizer Inc Overview
11.5.3 Pfizer Inc Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Pfizer Inc Dermatomyositis Drug Products and Services
11.5.5 Pfizer Inc Dermatomyositis Drug SWOT Analysis
11.5.6 Pfizer Inc Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Information
11.6.2 Eli Lilly and Company Overview
11.6.3 Eli Lilly and Company Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Eli Lilly and Company Dermatomyositis Drug Products and Services
11.6.5 Eli Lilly and Company Dermatomyositis Drug SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Information
11.7.2 F. Hoffmann-La Roche Ltd Overview
11.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Products and Services
11.7.5 F. Hoffmann-La Roche Ltd Dermatomyositis Drug SWOT Analysis
11.7.6 F. Hoffmann-La Roche Ltd Recent Developments
11.8 Hope Pharmaceuticals Inc
11.8.1 Hope Pharmaceuticals Inc Company Information
11.8.2 Hope Pharmaceuticals Inc Overview
11.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Products and Services
11.8.5 Hope Pharmaceuticals Inc Dermatomyositis Drug SWOT Analysis
11.8.6 Hope Pharmaceuticals Inc Recent Developments
11.9 Idera Pharmaceuticals Inc
11.9.1 Idera Pharmaceuticals Inc Company Information
11.9.2 Idera Pharmaceuticals Inc Overview
11.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Products and Services
11.9.5 Idera Pharmaceuticals Inc Dermatomyositis Drug SWOT Analysis
11.9.6 Idera Pharmaceuticals Inc Recent Developments
11.10 KPI Therapeutics Inc
11.10.1 KPI Therapeutics Inc Company Information
11.10.2 KPI Therapeutics Inc Overview
11.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 KPI Therapeutics Inc Dermatomyositis Drug Products and Services
11.10.5 KPI Therapeutics Inc Dermatomyositis Drug SWOT Analysis
11.10.6 KPI Therapeutics Inc Recent Developments
11.11 Marathon Pharmaceuticals LLC
11.11.1 Marathon Pharmaceuticals LLC Company Information
11.11.2 Marathon Pharmaceuticals LLC Overview
11.11.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Products and Services
11.11.5 Marathon Pharmaceuticals LLC Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Dermatomyositis Drug Value Chain Analysis
12.2 Dermatomyositis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dermatomyositis Drug Production Mode & Process
12.4 Dermatomyositis Drug Sales and Marketing
12.4.1 Dermatomyositis Drug Sales Channels
12.4.2 Dermatomyositis Drug Distributors
12.5 Dermatomyositis Drug Customers
13 Market Dynamics
13.1 Dermatomyositis Drug Industry Trends
13.2 Dermatomyositis Drug Market Drivers
13.3 Dermatomyositis Drug Market Challenges
13.4 Dermatomyositis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Dermatomyositis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Abatacept
Table 3. Major Manufacturers of Baricitinib
Table 4. Major Manufacturers of Dalazatide
Table 5. Major Manufacturers of Immune Globulin
Table 6. Major Manufacturers of IMO-8400
Table 7. Major Manufacturers of Others
Table 8. Global Dermatomyositis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Dermatomyositis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Dermatomyositis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Dermatomyositis Drug Revenue Market Share by Region (2018-2023)
Table 12. Global Dermatomyositis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Dermatomyositis Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Dermatomyositis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 15. Global Dermatomyositis Drug Sales by Region (2018-2023) & (K Pcs)
Table 16. Global Dermatomyositis Drug Sales Market Share by Region (2018-2023)
Table 17. Global Dermatomyositis Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Dermatomyositis Drug Sales Market Share by Region (2024-2034)
Table 19. Global Dermatomyositis Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 20. Global Dermatomyositis Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 21. Global Dermatomyositis Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 22. Global Dermatomyositis Drug Revenue Share by Manufacturers (2018-2023)
Table 23. Global Dermatomyositis Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 24. Global Key Players of Dermatomyositis Drug, Industry Ranking, 2021 VS 2024
Table 25. Global Dermatomyositis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Dermatomyositis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dermatomyositis Drug as of 2024)
Table 27. Global Key Manufacturers of Dermatomyositis Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Dermatomyositis Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Dermatomyositis Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 32. Global Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Dermatomyositis Drug Sales Quantity Share by Type (2018-2023)
Table 34. Global Dermatomyositis Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Global Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Dermatomyositis Drug Revenue Share by Type (2018-2023)
Table 38. Global Dermatomyositis Drug Revenue Share by Type (2024-2034)
Table 39. Dermatomyositis Drug Price by Type (2018-2023) & (USD/Pcs)
Table 40. Global Dermatomyositis Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 42. Global Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Dermatomyositis Drug Sales Quantity Share by Application (2018-2023)
Table 44. Global Dermatomyositis Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Global Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Dermatomyositis Drug Revenue Share by Application (2018-2023)
Table 48. Global Dermatomyositis Drug Revenue Share by Application (2024-2034)
Table 49. Dermatomyositis Drug Price by Application (2018-2023) & (USD/Pcs)
Table 50. Global Dermatomyositis Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Dermatomyositis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 52. North America Dermatomyositis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 53. North America Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 54. North America Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 56. North America Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 58. North America Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 60. North America Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 62. North America Dermatomyositis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 63. North America Dermatomyositis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Dermatomyositis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 65. North America Dermatomyositis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Dermatomyositis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 67. Europe Dermatomyositis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 68. Europe Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 69. Europe Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 71. Europe Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 73. Europe Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 75. Europe Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 77. Europe Dermatomyositis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 78. Europe Dermatomyositis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Dermatomyositis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 80. Europe Dermatomyositis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Dermatomyositis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 82. China Dermatomyositis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 83. China Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 84. China Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 86. China Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 88. China Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 90. China Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Dermatomyositis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 92. APAC Dermatomyositis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 93. APAC Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 94. APAC Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 96. APAC Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 98. APAC Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 100. APAC Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Dermatomyositis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 102. APAC Dermatomyositis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 103. APAC Dermatomyositis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Dermatomyositis Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 105. APAC Dermatomyositis Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 109. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 113. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Dermatomyositis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 120. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. MedImmune LLC Company Information
Table 122. MedImmune LLC Description and Overview
Table 123. MedImmune LLC Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 124. MedImmune LLC Dermatomyositis Drug Product and Services
Table 125. MedImmune LLC Dermatomyositis Drug SWOT Analysis
Table 126. MedImmune LLC Recent Developments
Table 127. Neovacs SA Company Information
Table 128. Neovacs SA Description and Overview
Table 129. Neovacs SA Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 130. Neovacs SA Dermatomyositis Drug Product and Services
Table 131. Neovacs SA Dermatomyositis Drug SWOT Analysis
Table 132. Neovacs SA Recent Developments
Table 133. Novartis AG Company Information
Table 134. Novartis AG Description and Overview
Table 135. Novartis AG Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 136. Novartis AG Dermatomyositis Drug Product and Services
Table 137. Novartis AG Dermatomyositis Drug SWOT Analysis
Table 138. Novartis AG Recent Developments
Table 139. Octapharma AG Company Information
Table 140. Octapharma AG Description and Overview
Table 141. Octapharma AG Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 142. Octapharma AG Dermatomyositis Drug Product and Services
Table 143. Octapharma AG Dermatomyositis Drug SWOT Analysis
Table 144. Octapharma AG Recent Developments
Table 145. Pfizer Inc Company Information
Table 146. Pfizer Inc Description and Overview
Table 147. Pfizer Inc Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 148. Pfizer Inc Dermatomyositis Drug Product and Services
Table 149. Pfizer Inc Dermatomyositis Drug SWOT Analysis
Table 150. Pfizer Inc Recent Developments
Table 151. Eli Lilly and Company Company Information
Table 152. Eli Lilly and Company Description and Overview
Table 153. Eli Lilly and Company Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 154. Eli Lilly and Company Dermatomyositis Drug Product and Services
Table 155. Eli Lilly and Company Dermatomyositis Drug SWOT Analysis
Table 156. Eli Lilly and Company Recent Developments
Table 157. F. Hoffmann-La Roche Ltd Company Information
Table 158. F. Hoffmann-La Roche Ltd Description and Overview
Table 159. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 160. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product and Services
Table 161. F. Hoffmann-La Roche Ltd Dermatomyositis Drug SWOT Analysis
Table 162. F. Hoffmann-La Roche Ltd Recent Developments
Table 163. Hope Pharmaceuticals Inc Company Information
Table 164. Hope Pharmaceuticals Inc Description and Overview
Table 165. Hope Pharmaceuticals Inc Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 166. Hope Pharmaceuticals Inc Dermatomyositis Drug Product and Services
Table 167. Hope Pharmaceuticals Inc Dermatomyositis Drug SWOT Analysis
Table 168. Hope Pharmaceuticals Inc Recent Developments
Table 169. Idera Pharmaceuticals Inc Company Information
Table 170. Idera Pharmaceuticals Inc Description and Overview
Table 171. Idera Pharmaceuticals Inc Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 172. Idera Pharmaceuticals Inc Dermatomyositis Drug Product and Services
Table 173. Idera Pharmaceuticals Inc Dermatomyositis Drug SWOT Analysis
Table 174. Idera Pharmaceuticals Inc Recent Developments
Table 175. KPI Therapeutics Inc Company Information
Table 176. KPI Therapeutics Inc Description and Overview
Table 177. KPI Therapeutics Inc Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 178. KPI Therapeutics Inc Dermatomyositis Drug Product and Services
Table 179. KPI Therapeutics Inc Dermatomyositis Drug SWOT Analysis
Table 180. KPI Therapeutics Inc Recent Developments
Table 181. Marathon Pharmaceuticals LLC Company Information
Table 182. Marathon Pharmaceuticals LLC Description and Overview
Table 183. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 184. Marathon Pharmaceuticals LLC Dermatomyositis Drug Product and Services
Table 185. Marathon Pharmaceuticals LLC Recent Developments
Table 186. Key Raw Materials Lists
Table 187. Raw Materials Key Suppliers Lists
Table 188. Dermatomyositis Drug Distributors List
Table 189. Dermatomyositis Drug Customers List
Table 190. Dermatomyositis Drug Market Trends
Table 191. Dermatomyositis Drug Market Drivers
Table 192. Dermatomyositis Drug Market Challenges
Table 193. Dermatomyositis Drug Market Restraints
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Dermatomyositis Drug Product Picture
Figure 2. Global Dermatomyositis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Dermatomyositis Drug Market Share by Type in 2024 & 2034
Figure 4. Abatacept Product Picture
Figure 5. Baricitinib Product Picture
Figure 6. Dalazatide Product Picture
Figure 7. Immune Globulin Product Picture
Figure 8. IMO-8400 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Dermatomyositis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 11. Global Dermatomyositis Drug Market Share by Application in 2024 & 2034
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Dermatomyositis Drug Report Years Considered
Figure 16. Global Dermatomyositis Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Dermatomyositis Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Dermatomyositis Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Dermatomyositis Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Dermatomyositis Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Dermatomyositis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Dermatomyositis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Dermatomyositis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Dermatomyositis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Dermatomyositis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Dermatomyositis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Dermatomyositis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Dermatomyositis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Dermatomyositis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Dermatomyositis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Dermatomyositis Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Dermatomyositis Drug Revenue in 2024
Figure 34. Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Dermatomyositis Drug Revenue Market Share by Company in 2024
Figure 40. North America Dermatomyositis Drug Sales Quantity Market Share by Company in 2024
Figure 41. North America Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Dermatomyositis Drug Revenue Share by Country (2018-2034)
Figure 46. North America Dermatomyositis Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Dermatomyositis Drug Sales Quantity Market Share by Company in 2024
Figure 50. Europe Dermatomyositis Drug Revenue Market Share by Company in 2024
Figure 51. Europe Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Dermatomyositis Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Dermatomyositis Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Dermatomyositis Drug Sales Quantity Market Share by Company in 2024
Figure 63. China Dermatomyositis Drug Revenue Market Share by Company in 2024
Figure 64. China Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Dermatomyositis Drug Sales Quantity Market Share by Company in 2024
Figure 69. APAC Dermatomyositis Drug Revenue Market Share by Company in 2024
Figure 70. APAC Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Dermatomyositis Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Dermatomyositis Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 80. India Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Dermatomyositis Drug Revenue Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Dermatomyositis Drug Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Dermatomyositis Drug Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Dermatomyositis Drug Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Dermatomyositis Drug Revenue Share by Country (2018-2034)
Figure 89. Brazil Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Dermatomyositis Drug Revenue (2018-2034) & (US$ Million)
Figure 94. Dermatomyositis Drug Value Chain
Figure 95. Dermatomyositis Drug Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed